Aberrant expression of cell-free nucleosomes in dermatomyositis/polymyositis.
biomarker
dermatomyositis
nucleosomes
polymyositis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
27
03
2020
revised:
15
10
2020
accepted:
23
10
2020
pubmed:
28
10
2020
medline:
9
3
2021
entrez:
27
10
2020
Statut:
ppublish
Résumé
Nucleosomes are typically located intracellularly, and extracellular levels of nucleosomes indicated the degree of cell death. We postulated aberrant nucleosomes expression in dermatomyositis (DM) and polymyositis (PM). To assess the aberrant expression of circulating nucleosomes in DM and polymyositis. 76 consecutive DM and PM patients from 1 September 2017 to 31 October 2018 were enrolled in this study, in addition to 20 healthy controls. The levels of circulating nucleosomes, with 16 kinds of detectable myositis-specific antibodies (MSAs) were detected in IIMs patients using enzyme-linked immunosorbent assay kit (ELISA). Receiver operating characteristic (ROC) curve analysis was performed for evaluating the ability of this candidate marker for detecting DM/PM. The results showed that the levels of circulating nucleosomes in DM/PM patients were significantly higher than that in normal individuals. Specifically, elevated levels of nucleosomes were associated with MDA5 Ab, ARS, and TIF1γAb. In addition, elevated levels of circulating nucleosomes correlated with skin eruption. This study has evidenced nucleosomes as a potential new biomarker of DM/PM. Aberrant nucleosomes expression occurs in myositis patients and the difference in nucleosomes expression between patients with and without skin eruption is statistically significant. A unique expression profile of elevated serum nucleosomes was detected in DM/PM-MDA5 Ab(+), ASS, and TIF1γAb(+).
Substances chimiques
Autoantibodies
0
Nucleosomes
0
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14460Subventions
Organisme : Chinese National Key Technology R&D Program, Ministry of Science and Technology
ID : 2017YFC0907604
Organisme : National Natural Science Foundation of China
ID : 81471615
Organisme : National Natural Science Foundation of China
ID : 81601430
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Lim J, Eftimov F, Raaphorst J, Aronica E, van der Kooi AJ. Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. Eur J Neurol. 2019;26(12):1494-1496.
Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol. 2005;23(5):724.
Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford, England). 2005;44(10):1282-1286.
Zhong Z, Lin F, Yang J, Zhang F, Zeng X, You X. Pregnancy in polymyositis or dermatomyositis: retrospective results from a tertiary centre in China. Rheumatology (Oxford, England). 2017;56(8):1272-1275.
Volc-Platzer B. Dermatomyositis-update. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete. 2015;66(8):604-610.
Livermore P, Gray S, Mulligan K, Stinson JN, Wedderburn LR, Gibson F. Being on the juvenile dermatomyositis rollercoaster: a qualitative study. Pediatr Rheumatol Online J. 2019;17(1):30.
Khattab H, Rafai MA, el Moutawakil B, el Otmani H, Mikou N, Bouayed K. Associated pediatric neuromyelitis optica and dermatomyositis: a case report. Rev Neurol. 2019;175:489-492.
Tyagi M, Khan SA, Bhattacharya S, et al. Techniques to access histone modifications and variants in cancer. Methods Mol Biol. 2015;1238:251-272.
Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease. Nephrol Dial Transplant. 2018;33(11):1875-1886.
Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis. Cytokine. 2013;62(2):244-252.
Amary F, Berisha F, Ye H, et al. H3F3A (histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41(8):1059-1068.
Holdenrieder S, Eichhorn P, Beuers U, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann NY Acad Sci. 2006;1075:318-327.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269-278.
McAnena P, Brown JA, Kerin MJ. Circulating nucleosomes and nucleosome modifications as biomarkers in cancer. Cancers (Basel). 2017;9(1):5.
Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci. 2009;46(1):1-24.
Surace AEA, Hedrich CM. The role of epigenetics in autoimmune/inflammatory disease. Front Immunol. 2019;10:1525.
Gabler C, Blank N, Hieronymus T, et al. Extranuclear detection of histones and nucleosomes in activated human lymphoblasts as an early event in apoptosis. Ann Rheum Dis. 2004;63(9):1135-1144.
Amoura Z, Piette JC, Chabre H, et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum. 1997;40(12):2217-2225.